Luz Magdaly Jimenez Gallardo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luz Magdaly Jimenez Gallardo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Adrián Rosas-Trujillo
Cardiology service at Instituto Nacional de Enfermedades Respiratorias, Mexico city, Mexico
1 shared publicationAlvaro Montañez-Orozco
Cardiology service at Instituto Nacional de Enfermedades Respiratorias, Mexico city, Mexico
1 shared publication- Alvaro Montañez-Orozco
Cardiology Service, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City 14080, Mexico
1 shared publication Angelia Jimenez-Valentín
Cardiology service at Instituto Nacional de Enfermedades Respiratorias, Mexico city, Mexico
1 shared publication- Armando Castorena-Maldonado
Direction for Medical Care in Pneumology at Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas” 4, Mexico City 14080, Mexico
1 shared publication Arturo Orea-Tejeda
Cardiology service at Instituto Nacional de Enfermedades Respiratorias, Mexico city, Mexico
1 shared publication
Latest Publications
- Open Access
- 11 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6466
Dynapenia and Sarcopenia in Post-COVID-19 Syndrome Hospitalized Patients Are Associated with Severe Reduction in Pulmonary Function
Background: After hospital discharge, post-COVID-19 syndrome has been observed to be associated with impaired diffusing capacity, respiratory muscle strength, and lung imaging abnormalities, in addition to loss of muscle mass/strength, sarcopenia, and obesity impact exercise tolerance, pulmonary functions, and overall prognosis. However, the relationship between lung function and the coexistence of obesity with low muscle strength and sarcopenia in post-COVID-19 patients remains poorly investigated. Therefore, our aim was to evaluate the association between lung function and the coexistence of obesity with dynapenia and sarcopenia in post-COVID-19 syndrome patients. Methods: This cross-sectional study included subjects who were hospitalized due to moderate to severe COVID-19, as confirmed by PCR testing. Subjects who could not be contacted, declined to participate, or died before the follow-up visit were excluded. Results: A total of 711 subjects were evaluated; the mean age was 53.64 ± 13.57 years, 12.4% had normal weight, 12.6% were dynapenic without obesity, 8.3% had sarcopenia, 41.6% had obesity, 21.2% had dynapenic obesity, and 3.8% had sarcopenic obesity. In terms of pulmonary function, the dynapenic subjects showed decreases of −3.45% in FEV1, −12.61 cmH2O in MIP, and -12.85 cmH2O in MEP. On the other hand, the sarcopenic subjects showed decreases of −6.14 cmH2O in MIP and −11.64 cmH2O in MEP. The dynapenic obesity group displayed a reduction of −12.13% in PEF. Conclusions: In post-COVID-19 syndrome, dynapenia and sarcopenia—both with and without obesity—have been associated with lower lung function.
- 11 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (20) , 6466
Open AccessDynapenia and Sarcopenia in Post-COVID-19 Syndrome Hospitalized Patients Are Associated with Severe Reduction in Pulmonary Function
Background: After hospital discharge, post-COVID-19 syndrome has been observed to be associated with impaired diffusing capacity, respiratory muscle strength, and lung imaging abnormalities, in addition to loss of muscle mass/strength, sarcopenia, and obesity impact exercise tolerance, pulmonary functions, and overall prognosis. However, the relationship between lung function and the coexistence of obesity with low muscle strength and sarcopenia in post-COVID-19 patients remains poorly investigated. Therefore, our aim was to evaluate the association between lung function and the coexistence of obesity with dynapenia and sarcopenia in post-COVID-19 syndrome patients. Methods: This cross-sectional study included subjects who were hospitalized due to moderate to severe COVID-19, as confirmed by PCR testing. Subjects who could not be contacted, declined to participate, or died before the follow-up visit were excluded. Results: A total of 711 subjects were evaluated; the mean age was 53.64 ± 13.57 years, 12.4% had normal weight, 12.6% were dynapenic without obesity, 8.3% had sarcopenia, 41.6% had obesity, 21.2% had dynapenic obesity, and 3.8% had sarcopenic obesity. In terms of pulmonary function, the dynapenic subjects showed decreases of −3.45% in FEV1, −12.61 cmH2O in MIP, and -12.85 cmH2O in MEP. On the other hand, the sarcopenic subjects showed decreases of −6.14 cmH2O in MIP and −11.64 cmH2O in MEP. The dynapenic obesity group displayed a reduction of −12.13% in PEF. Conclusions: In post-COVID-19 syndrome, dynapenia and sarcopenia—both with and without obesity—have been associated with lower lung function.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3312
Impact of thrombomodulin on mortality in hospitalized patients with COVID-19: A cohort-study
Background: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. The clinical curse includes from an asymptomatic course to death. Thrombomodulin (BDCA3) is predominantly expressed on vascular endothelial cells, BDCA3 is well known for its anticoagulant activity. Objective: To determine the impact of thrombomodulin on mortality in COVID-19 hospitalizated patients. Hypothesis: patients with alterations of BDCA3 will have more mortality risk. Methods: In a cohort study, patients >18 years hospitalized with diagnosis COVID-19 were included and BDCA3 was quantified. Results: A total 165 patients with COVID-19 and BDCA3 were evaluated, the age was 57.2±12.9. Subjects were classified in survivors and no survivors. No differences in comorbidities were observed between groups. IMV on admission and glucose were grater in no survivors. Those patients with BDCA23 greater than 3600 pg/mL have 3.5 times the risk of dying compared to those patients with lower BDCA3, adjusted for cardiovascular disease, thyroid disease, enoxaparin dose, direct bilirubin, and sex. Conclusion: Patients with BDCA3 greater had higher mortality risk, it could be in response to worse inflammatory process.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3312
Impact of thrombomodulin on mortality in hospitalized patients with COVID-19: A cohort-study
Background: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. The clinical curse includes from an asymptomatic course to death. Thrombomodulin (BDCA3) is predominantly expressed on vascular endothelial cells, BDCA3 is well known for its anticoagulant activity. Objective: To determine the impact of thrombomodulin on mortality in COVID-19 hospitalizated patients. Hypothesis: patients with alterations of BDCA3 will have more mortality risk. Methods: In a cohort study, patients >18 years hospitalized with diagnosis COVID-19 were included and BDCA3 was quantified. Results: A total 165 patients with COVID-19 and BDCA3 were evaluated, the age was 57.2±12.9. Subjects were classified in survivors and no survivors. No differences in comorbidities were observed between groups. IMV on admission and glucose were grater in no survivors. Those patients with BDCA23 greater than 3600 pg/mL have 3.5 times the risk of dying compared to those patients with lower BDCA3, adjusted for cardiovascular disease, thyroid disease, enoxaparin dose, direct bilirubin, and sex. Conclusion: Patients with BDCA3 greater had higher mortality risk, it could be in response to worse inflammatory process.